These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28260071)

  • 21. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
    Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
    Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AXL and acquired resistance to EGFR inhibitors.
    Postel-Vinay S; Ashworth A
    Nat Genet; 2012 Jul; 44(8):835-6. PubMed ID: 22836088
    [No Abstract]   [Full Text] [Related]  

  • 23. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
    Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
    Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
    Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
    Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
    Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
    Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axl is a prognostic marker in oral squamous cell carcinoma.
    Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
    Kim NY; Suh YA; Kim S; Lee C
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32219334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
    Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
    Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
    Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
    Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.
    Song X; Wang H; Logsdon CD; Rashid A; Fleming JB; Abbruzzese JL; Gomez HF; Evans DB; Wang H
    Cancer; 2011 Feb; 117(4):734-43. PubMed ID: 20922806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axl Is a Potential Cancer Prognostic Marker for the Migration and Invasion of Nasopharyngeal Carcinoma.
    Jiang C; Zhou L; Wang H; Zhang Q; Xu Y
    Adv Clin Exp Med; 2016; 25(3):531-7. PubMed ID: 27629742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
    Lee YJ; Kim SY; Lee C
    Mol Med Rep; 2019 Apr; 19(4):3230-3236. PubMed ID: 30816529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
    Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
    Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
    Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
    Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
    Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
    Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
    EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AXL regulates mesothelioma proliferation and invasiveness.
    Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
    Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.